Home/Sionna Therapeutics/Dr. Martin Mense
DM

Dr. Martin Mense

Senior Vice President, Biology

Sionna Therapeutics

Therapeutic Areas

Sionna Therapeutics Pipeline

DrugIndicationPhase
SION-638Cystic Fibrosis (F508del mutation)Phase 1
SION-109Cystic Fibrosis (F508del mutation)Preclinical
SION-451Cystic Fibrosis (F508del mutation)Preclinical
SION-676Cystic Fibrosis (F508del mutation)Preclinical